Previous 10 | Next 10 |
home / stock / dhr / dhr articles
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Danaher Corporation ("Danaher" or the "...
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NASDAQ:RAIN) Lifshitz Law PLLC announces investigation into possible securiti...
WHY: NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher...
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation ("Da...
NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders ...
Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 7.47% on an annualized basis producing an average annual return of 18.08%....
Monday, Danaher Corporation (NYSE: DHR) had agreed to acquire Abcam plc (NASDAQ: ABCM) for $24.00 per share in cash, or a total...
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management. ...
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Danaher Corporation (NYSE:DHR)? Did you p...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...